• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Cybin Inc.

    6/11/25 2:32:32 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYBN alert in real time by email
    6-K 1 cybininc-form6xk06x11x2025.htm 6-K Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of June, 2025.
    Commission File Number: 001-40673


    Cybin Inc.
    (Exact Name of Registrant as Specified in Charter)

    100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
    Form 20-F □ Form 40-F ⊠







    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    CYBIN INC.
    (Registrant)
     
    Date:June 11, 2025By:
    /s/ Doug Drysdale    
    Name:Doug Drysdale
    Title:Chief Executive Officer





    EXHIBIT INDEX

    99.1
    News Release dated June 11, 2025

    Get the next $CYBN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYBN

    DatePrice TargetRatingAnalyst
    3/13/2025$35.00Buy
    Guggenheim
    11/22/2021$8.00 → $10.00Buy
    HC Wainwright & Co.
    11/19/2021Buy → Hold
    Maxim Group
    10/5/2021$7.00Outperform
    Oppenheimer
    8/26/2021$9.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CYBN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

      - Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder ("MDD") with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) - - Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company's commercialization and manufacturing capabilities - - Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin's clinical-stage pipeline - Cybin Inc. (NYSE:CYBN) (Cboe Canada CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by

      6/13/25 7:45:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

      Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Conference, taking place June 16-17, 2025. Mr. Drysdale's fireside chat will be available on demand beginning on Monday, June 16, 2025, at 7:00 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company's investor r

      6/12/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin to Participate in the 2025 Psychedelic Science Conference

      - Cybin CEO Doug Drysdale to participate in a panel discussion titled "The Home Stretch: Pivotal Trials and Preparing for Launch" on June 19, 2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will be speaking at the Psychedelic Science 2025 Conference taking place June 16-20, 2025 in Denver, Colorado. The details are as follows: Panel Title: The Home Stretch: Pivotal Trials and Preparing for Launch Date and Time: Thursday,

      6/11/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care